

Daniela Maria Cirillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/677002/publications.pdf>

Version: 2024-02-01

276
papers

15,592
citations

19657

61
h-index

23533

111
g-index

292
all docs

292
docs citations

292
times ranked

12722
citing authors

#	ARTICLE	IF	CITATIONS
1	QIArearch QuantiFERON-TB for the diagnosis of <i>Mycobacterium tuberculosis</i> infection. European Respiratory Journal, 2022, 59, 2102563.	6.7	11
2	<i>In vivo</i> microevolution of <i>Mycobacterium tuberculosis</i> and transient emergence of <i>atpE</i> _Ala63Pro mutation during treatment in a pre-XDR TB patient. European Respiratory Journal, 2022, 59, 2102102.	6.7	8
3	Anti-tuberculosis drug resistance in Slovakia, 2018–2019: The first whole-genome epidemiological study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022, 26, 100292.	1.3	3
4	Combined Host- and Pathogen-Directed Therapy for the Control of <i>Mycobacterium abscessus</i> Infection. Microbiology Spectrum, 2022, 10, e0254621.	3.0	12
5	Detection of NDM-1/5 and OXA-48 co-producing extensively drug-resistant hypervirulent <i>Klebsiella pneumoniae</i> in Northern Italy. Journal of Global Antimicrobial Resistance, 2022, 28, 146-150.	2.2	15
6	Draft Genome Sequences of 77 Endemic Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Strains of SIT41 (TUR) Spoligotype from Bulgaria. Microbiology Resource Announcements, 2022, , e0111121.	0.6	0
7	Whole genome sequencing of isoniazid monoresistant clinical isolates of <i>Mycobacterium tuberculosis</i> reveals novel genetic polymorphisms. Tuberculosis, 2022, 133, 102173.	1.9	1
8	Rapid SARS-CoV-2 Intra-Host and Within-Household Emergence of Novel Haplotypes. Viruses, 2022, 14, 399.	3.3	5
9	Ancient and recent differences in the intrinsic susceptibility of <i>Mycobacterium tuberculosis</i> complex to pretomanid. Journal of Antimicrobial Chemotherapy, 2022, 77, 1685-1693.	3.0	34
10	Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews, 2022, 35, e0022721.	13.6	26
11	The 2021 WHO catalogue of <i>Mycobacterium tuberculosis</i> complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe, The, 2022, 3, e265-e273.	7.3	114
12	Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting. Tuberculosis, 2022, 134, 102185.	1.9	4
13	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. JCI Insight, 2022, 7, .	5.0	15
14	Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal, 2022, 59, 2200166.	6.7	15
15	Chromogranin A plasma levels predict mortality in COVID-19. PLoS ONE, 2022, 17, e0267235.	2.5	9
16	Chitinase-3-like protein-1 at hospital admission predicts COVID-19 outcome: a prospective cohort study. Scientific Reports, 2022, 12, 7606.	3.3	6
17	Whole genome sequencing of multidrug-resistant <i>Mycobacterium tuberculosis</i> isolates collected in the Czech Republic, 2005–2020. Scientific Reports, 2022, 12, 7149.	3.3	14
18	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59, 2200388.	6.7	15

#	ARTICLE	IF	CITATIONS
19	Fragmentation of Healthcare Services as a Possible Determinant of the Low Completion for the Tuberculosis Cascade of Prevention among Asylum Seekers: Results from a Prospective Study with Historical Comparison. <i>Pathogens</i> , 2022, 11, 613.	2.8	0
20	Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape. <i>EBioMedicine</i> , 2022, 82, 104174.	6.1	11
21	Use of a Whole Genome Sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017-2019: an ECDC pilot study. <i>European Respiratory Journal</i> , 2021, 57, 2002272.	6.7	27
22	Hepcidin levels predict COVID-19 severity and mortality in a cohort of hospitalized Italian patients. <i>American Journal of Hematology</i> , 2021, 96, E32-E35.	4.1	58
23	Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe. <i>European Respiratory Journal</i> , 2021, 57, 2003890.	6.7	36
24	Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	43
25	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 288.e1-288.e4.	6.0	9
26	Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection. <i>Haematologica</i> , 2021, 106, 641-646.	3.5	17
27	Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. <i>European Respiratory Journal</i> , 2021, 57, 2002338.	6.7	58
28	Microbiological Diagnosis of Tuberculosis Disease. , 2021, , 87-96.		0
29	Framework for the evaluation of new tests for tuberculosis infection. <i>European Respiratory Journal</i> , 2021, 58, 2004078.	6.7	9
30	Tackling TB in migrants arriving at Europe's southern border. <i>International Journal of Infectious Diseases</i> , 2021, , .	3.3	3
31	Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs. <i>Emerging Infectious Diseases</i> , 2021, 27, 985-987.	4.3	12
32	Is deployment of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso. <i>BMC Infectious Diseases</i> , 2021, 21, 346.	2.9	0
33	Integrative transnational analysis to dissect tuberculosis transmission events along the migratory route from Africa to Europe. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	7
34	Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia. <i>Research in Microbiology</i> , 2021, 172, 103816.	2.1	2
35	Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. <i>Future Microbiology</i> , 2021, 16, 399-407.	2.0	0
36	Tests for tuberculosis infection: landscape analysis. <i>European Respiratory Journal</i> , 2021, 58, 2100167.	6.7	35

#	ARTICLE	IF	CITATIONS
37	Assessment of the GenoType MTBDRsl VER 2.0 compared to the phenotypic drug susceptibility testing and whole genome sequencing for the rapid detection of resistance to fluoroquinolone and second-line injectable drugs among rifampicin-resistant Mycobacterium tuberculosis isolates. Archives of Microbiology, 2021, 203, 3989-3996.	2.2	7
38	Outbreak of pre- and extensively drug-resistant tuberculosis in northern Italy: urgency of cross-border, multidimensional, surveillance systems. European Respiratory Journal, 2021, 58, 2100839.	6.7	1
39	Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy. Emerging Infectious Diseases, 2021, 27, 1416-1426.	4.3	8
40	Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. Journal of Neurology, 2021, 268, 4436-4442.	3.6	63
41	Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?. European Respiratory Journal, 2021, 58, 2100959.	6.7	5
42	Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0116421.	3.2	35
43	SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiology Spectrum, 2021, 9, e0025021.	3.0	7
44	Chronic infection by nontypeable <i>Haemophilus influenzae</i> fuels airway inflammation. ERJ Open Research, 2021, 7, 00614-2020.	2.6	17
45	Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy. European Respiratory Journal, 2021, 58, 2102099.	6.7	2
46	Population structure, biogeography and transmissibility of Mycobacterium tuberculosis. Nature Communications, 2021, 12, 6099.	12.8	59
47	CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. Molecular Medicine, 2021, 27, 129.	4.4	41
48	Equivalence of the GeneXpert System and GeneXpert Omni System for tuberculosis and rifampicin resistance detection. PLoS ONE, 2021, 16, e0261442.	2.5	2
49	Multicenter evaluation of xpert MTB/RIF ultra tests reporting detection of "Trace" of Mycobacterium tuberculosis DNA. International Journal of Mycobacteriology, 2021, 10, 101.	0.6	6
50	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clinical Infectious Diseases, 2020, 70, 1774-1780.	5.8	59
51	The neglected role of Faith-based Organizations in prevention and control of COVID-19 in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 784-786.	1.8	7
52	A New Model of Chronic Mycobacterium abscessus Lung Infection in Immunocompetent Mice. International Journal of Molecular Sciences, 2020, 21, 6590.	4.1	14
53	What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?. Clinical Microbiology and Infection, 2020, 26, 1453-1455.	6.0	14
54	A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7

#	ARTICLE	IF	CITATIONS
55	Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. <i>Respiratory Medicine</i> , 2020, 175, 106204.	2.9	17
56	Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates – the EUCAST broth microdilution reference method for MIC determination. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1488-1492.	6.0	49
57	Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	57
58	<p>Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2795-2800.	2.7	12
59	Intermittent regimens for tuberculosis treatment: Back to the Future?. <i>European Respiratory Journal</i> , 2020, 56, 2002510.	6.7	0
60	How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	18
61	Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	46
62	GenomeMap: Within-Species Genome-Wide dN/dS Estimation from over 10,000 Genomes. <i>Molecular Biology and Evolution</i> , 2020, 37, 2450-2460.	8.9	25
63	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89
64	Screening of inmates transferred to Spain reveals a Peruvian prison as a reservoir of persistent Mycobacterium tuberculosis MDR strains and mixed infections. <i>Scientific Reports</i> , 2020, 10, 2704.	3.3	12
65	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	3.3	26
66	Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran. <i>Journal of Clinical Medicine</i> , 2020, 9, 465.	2.4	20
67	Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. <i>PLoS Medicine</i> , 2020, 17, e1003008.	8.4	74
68	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
69	Whole-Genome Sequences of Two NDM-1-Producing Pseudomonas aeruginosa Strains Isolated in a Clinical Setting in Albania in 2018. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	4
70	Celebrating World Tuberculosis Day at the time of COVID-19. <i>European Respiratory Journal</i> , 2020, 55, 2000650.	6.7	41
71	Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries. <i>EClinicalMedicine</i> , 2020, 20, 100268.	7.1	26
72	Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	29

#	ARTICLE	IF	CITATIONS
73	The prospects for the <sc>SARS</sc> â€CoVâ€2 pandemic in Africa. EMBO Molecular Medicine, 2020, 12, e12488.	6.9	37
74	Comparison of core-genome MLST, coreSNP and PFGE methods for Klebsiella pneumoniae cluster analysis. Microbial Genomics, 2020, 6, .	2.0	34
75	Applying a Standardized Approach to Strengthen Performances of GeneXpert Networks programme: lessons learned from Burkina Faso, 2019. ERJ Open Research, 2020, 6, 00283-2020.	2.6	1
76	Genomic analysis of cardiac surgery-associated Mycobacterium chimaera infections in Italy. PLoS ONE, 2020, 15, e0239273.	2.5	8
77	Precision medicine and public health interventions: tuberculosis as a model?. Lancet Public Health, The, 2019, 4, e374.	10.0	11
78	App-based symptoms screening with Xpert MTB/RIF Ultra assay used for active tuberculosis detection in migrants at point of arrivals in Italy: The E-DETECT TB intervention analysis. PLoS ONE, 2019, 14, e0218039.	2.5	12
79	Genome-based taxonomic revision detects a number of synonymous taxa in the genus Mycobacterium. Infection, Genetics and Evolution, 2019, 75, 103983.	2.3	61
80	Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	47
81	Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests. Journal of Infectious Diseases, 2019, 220, S126-S135.	4.0	10
82	Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nature Reviews Microbiology, 2019, 17, 533-545.	28.6	237
83	Emergence of two novel sequence types (3366 and 3367) NDM-1- and OXA-48-co-producing K. pneumoniae in Italy. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1687-1691.	2.9	20
84	Isolation of the first New Delhi metallo-ÃŸ-lactamase-1 (NDM-1)-producing and colistin-resistant Klebsiella pneumoniae sequence type ST15 from a digestive carrier in Albania, May 2018. Journal of Global Antimicrobial Resistance, 2019, 17, 142-144.	2.2	8
85	Isoniazid Resistance in <i>Mycobacterium tuberculosis</i> Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	32
86	DeepAMR for predicting co-occurrent resistance of <i>Mycobacterium tuberculosis</i>. Bioinformatics, 2019, 35, 3240-3249.	4.1	38
87	Building the Framework for Standardized Clinical Laboratory Reporting of Next-generation Sequencing Data for Resistance-associated Mutations in Mycobacterium tuberculosis Complex. Clinical Infectious Diseases, 2019, 69, 1631-1633.	5.8	10
88	Hospital outbreak due to Clostridium difficile ribotype 018 (RT018) in Southern Germany. International Journal of Medical Microbiology, 2019, 309, 189-193.	3.6	16
89	Tuberculosis Surveillance and Control, Puerto Rico, 1898â€“2015. Emerging Infectious Diseases, 2019, 25, 538-546.	4.3	5
90	Exportation of MDR TB to Europe from Setting with Actively Transmitted Persistent Strains in Peru. Emerging Infectious Diseases, 2019, 25, 596-598.	4.3	7

#	ARTICLE	IF	CITATIONS
91	ASAP-GxNet project in Burkina Faso: fulfil country capacity gaps to ensure efficient utilisation of GeneXpert instruments in tuberculosis care and cascade. ERJ Open Research, 2019, 5, 00150-2018.	2.6	2
92	Whole-Genome Sequencing of Drug-Resistant <i>Mycobacterium tuberculosis</i> Strains, Tunisia, 2012–2016. Emerging Infectious Diseases, 2019, 25, 538-546.	4.3	17
93	Drug-Resistant Tuberculosis, Lebanon, 2016 – 2017. Emerging Infectious Diseases, 2019, 25, 564-568.	4.3	15
94	An innovative silicon-chip for sensitive real time PCR improvement in pathogen detection. Analyst, The, 2019, 144, 2353-2358.	3.5	9
95	The role of entry-screening procedures in the identification of multidrug-resistant <i>Mycobacterium tuberculosis</i> cluster cases amongst patients arriving in Europe from the horn of Africa, 2016-17. International Journal of Infectious Diseases, 2019, 79, 22.	3.3	0
96	Lack of association of novel mutation Asp397Gly in <i>afbB</i> gene with ethambutol resistance in clinical isolates of <i>Mycobacterium tuberculosis</i> . Tuberculosis, 2019, 115, 49-55.	1.9	3
97	Treating Primary Arthroprosthesis Infection Caused by <i>Mycobacterium abscessus</i> subsp. <i>abscessus</i> . Case Reports in Infectious Diseases, 2019, 2019, 1-7.	0.5	1
98	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	6.7	54
99	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal, 2019, 53, 1802089.	6.7	9
100	Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. Travel Medicine and Infectious Disease, 2019, 27, 39-45.	3.0	22
101	Antibiotic resistance prediction for <i>Mycobacterium tuberculosis</i> from genome sequence data with Mykrobe. Wellcome Open Research, 2019, 4, 191.	1.8	103
102	Towards standardisation: comparison of five whole genome sequencing (WGS) analysis pipelines for detection of epidemiologically linked tuberculosis cases. Eurosurveillance, 2019, 24, .	7.0	42
103	Whole genome sequencing in <i>Mycobacterium tuberculosis</i> . Annals of Translational Medicine, 2019, 7, S197-S197.	1.7	7
104	Single-center outbreak of <i>Pneumocystis jirovecii</i> pneumonia in heart transplant recipients. Transplant Infectious Disease, 2018, 20, e12880.	1.7	16
105	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017–update. European Respiratory Journal, 2018, 51, 1702678.	6.7	50
106	Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries. European Respiratory Journal, 2018, 51, 1800387.	6.7	29
107	A cluster of multidrug-resistant <i>Mycobacterium tuberculosis</i> among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infectious Diseases, The, 2018, 18, 431-440.	9.1	121
108	<i>Staphylococcus aureus</i> Impacts <i>Pseudomonas aeruginosa</i> Chronic Respiratory Disease in Murine Models. Journal of Infectious Diseases, 2018, 217, 933-942.	4.0	39

#	ARTICLE	IF	CITATIONS
109	Role of Disputed Mutations in the <i>rpoB</i> Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2018, 56, .	3.9	88
110	Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!. EBioMedicine, 2018, 29, 11-12.	6.1	5
111	EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU. Lancet Infectious Diseases, The, 2018, 18, 377.	9.1	25
112	Screening of migrants for tuberculosis identifies patients with multidrug-resistant tuberculosis but is not sufficient. Clinical Microbiology and Infection, 2018, 24, 918-919.	6.0	2
113	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infectious Diseases, The, 2018, 18, 675-683.	9.1	119
114	Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases, The, 2018, 18, 76-84.	9.1	474
115	MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ, 2018, 6, e5895.	2.0	148
116	Implementing TB control in a rural, resource-limited setting: the stop-TB Italia project in Senegal. Multidisciplinary Respiratory Medicine, 2018, 13, 41.	1.5	3
117	Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. New England Journal of Medicine, 2018, 379, 1403-1415.	27.0	405
118	Can we predict tuberculosis cure? What tools are available?. European Respiratory Journal, 2018, 52, 1801089.	6.7	73
119	Multidrug-resistant tuberculosis in Côte d'Ivoire from 1995 to 2016: Results of national surveys. European Journal of Microbiology and Immunology, 2018, 8, 91-94.	2.8	8
120	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports, 2018, 8, 15382.	3.3	75
121	Latent tuberculous infection among foreign-born individuals applying to shelters in the metropolitan area of Milan. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1160-1165.	1.2	5
122	A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis. BMC Infectious Diseases, 2018, 18, 431.	2.9	3
123	Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respiriology, 2018, 23, 1098-1113.	2.3	62
124	Whole genome sequencing of Mycobacterium tuberculosis. European Respiratory Journal, 2018, 52, 1801163.	6.7	35
125	Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. International Journal of Tuberculosis and Lung Disease, 2018, 22, 197-205.	1.2	29
126	Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium. European Respiratory Journal, 2018, 51, 1702604.	6.7	15

#	ARTICLE	IF	CITATIONS
127	Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	62
128	Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 661-666.	1.2	11
129	Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009â€“2016. European Respiratory Journal, 2018, 52, 1800070.	6.7	16
130	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
131	Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. International Journal of Tuberculosis and Lung Disease, 2018, 22, 17-25.	1.2	130
132	Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. Clinical Microbiology and Infection, 2018, 24, 60-64.	6.0	21
133	Mycobacterium abscessus, a taxonomic puzzle. International Journal of Systematic and Evolutionary Microbiology, 2018, 68, 467-469.	1.7	21
134	Mycobacterium decipiens sp. nov., a new species closely related to the Mycobacterium tuberculosis complex. International Journal of Systematic and Evolutionary Microbiology, 2018, 68, 3557-3562.	1.7	13
135	Automated detection of bacterial growth on 96-well plates for high-throughput drug susceptibility testing of Mycobacterium tuberculosis. Microbiology (United Kingdom), 2018, 164, 1522-1530.	1.8	21
136	Characterization of murine model of chronic M. abscessus respiratory infection.. , 2018, , .		0
137	Prevalence and molecular characteristics of Staphylococcus aureus, including methicillin resistant strains, isolated from bulk can milk and raw milk products in pastoral communities of South-West Uganda. BMC Infectious Diseases, 2017, 17, 422.	2.9	53
138	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. European Respiratory Journal, 2017, 49, 1602242.	6.7	11
139	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1700356.	6.7	3
140	From latent to patent: rethinking prediction of tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 243-244.	10.7	26
141	The new phylogeny of the genus Mycobacterium : The old and the news. Infection, Genetics and Evolution, 2017, 56, 19-25.	2.3	128
142	The New Xpert MTB/RIF Ultra: Improving Detection of <i>Mycobacterium tuberculosis</i> and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. MBio, 2017, 8, .	4.1	431
143	Aiming for zero tuberculosis transmission in low-burden countries. Lancet Respiratory Medicine,the, 2017, 5, 846-848.	10.7	13
144	<i>Mycobacterium abscessus</i> in patients with cystic fibrosis: low impact of inter-human transmission in Italy. European Respiratory Journal, 2017, 50, 1602525.	6.7	63

#	ARTICLE	IF	CITATIONS
145	Evolution of Phenotypic and Molecular Drug Susceptibility Testing. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1019, 221-246.	1.6	28
146	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. <i>Tuberculosis</i> , 2017, 106, 38-43.	1.9	89
147	Control of infectious mortality due to carbapenemase-producing <i>Klebsiella pneumoniae</i> in hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 114-119.	2.4	33
148	Whole genome sequencing of <i>Mycobacterium tuberculosis</i> for detection of drug resistance: a systematic review. <i>Clinical Microbiology and Infection</i> , 2017, 23, 61-68.	6.0	95
149	A standardised method for interpreting the association between mutations and phenotypic drug resistance in <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2017, 50, 1701354.	6.7	273
150	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701414.	6.7	21
151	Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey. <i>Scientific Reports</i> , 2017, 7, 17672.	3.3	28
152	Molecular epidemiology of Panton-Valentine Leukocidin-positive community-acquired methicillin resistant <i>Staphylococcus aureus</i> isolates in pastoral communities of rural south western Uganda. <i>BMC Infectious Diseases</i> , 2017, 17, 24.	2.9	27
153	Evaluation of <i>Mycobacterium tuberculosis</i> viability in OMNIgene-SPLITUM reagent upon multi-day transport at ambient temperature. <i>BMC Infectious Diseases</i> , 2017, 17, 663.	2.9	6
154	<i>Mycobacterium persicum</i> sp. nov., a novel species closely related to <i>Mycobacterium kansasii</i> and <i>Mycobacterium gastri</i> . <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2017, 67, 1766-1770.	1.7	26
155	Mozambique's journey toward accreditation of the National Tuberculosis Reference Laboratory. <i>African Journal of Laboratory Medicine</i> , 2017, 6, 491.	0.6	5
156	Molecular typing of <i>Mycobacterium Abscessus</i> isolated from cystic fibrosis patients. <i>International Journal of Mycobacteriology</i> , 2017, 6, 138.	0.6	13
157	Modeling polymicrobial infections in the pathogenesis of respiratory diseases. , 2017, , .		0
158	Provision of systematic testing for active TB in refugees at CPSA centers. , 2017, , .		0
159	Modulation of QuantiFERON-TB-Gold Plus response in patients with active tuberculosis and latent infection during treatment. , 2017, , .		0
160	Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India. <i>Emerging Infectious Diseases</i> , 2016, 22, 463-468.	4.3	20
161	MIRU-VNTR Genotyping of <i>Mycobacterium tuberculosis</i> Strains Using QIAxcel Technology: A Multicentre Evaluation Study. <i>PLoS ONE</i> , 2016, 11, e0149435.	2.5	18
162	Population-based resistance of <i>Mycobacterium tuberculosis</i> isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1185-1192.	9.1	151

#	ARTICLE	IF	CITATIONS
163	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1751-1763.	6.7	165
164	Delamanid susceptibility testing of <i>Mycobacterium tuberculosis</i> using the resazurin microtitre assay and the BACTEC [®] MGIT [®] 960 system. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1532-1539.	3.0	68
165	Preliminary data on precision of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 48, 955-956.	6.7	10
166	First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. <i>Journal of Infection</i> , 2016, 73, 588-597.	3.3	101
167	A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2956-2962.	3.9	38
168	A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2963-2968.	3.9	42
169	Genotypic and phenotypic relatedness of <i>Pseudomonas aeruginosa</i> isolates among the major cystic fibrosis patient cohort in Italy. <i>BMC Microbiology</i> , 2016, 16, 142.	3.3	13
170	The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis. <i>BMC Infectious Diseases</i> , 2016, 16, 366.	2.9	41
171	Delamanid susceptibility testing of <i>Mycobacterium tuberculosis</i> using the resazurin microtitre assay and the BACTEC [®] MGIT [®] 960 system – authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3625-3625.	3.0	5
172	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. <i>European Respiratory Journal</i> , 2016, 48, 1411-1419.	6.7	119
173	<i>Mycobacterium tuberculosis</i> lineage 4 comprises globally distributed and geographically restricted sublineages. <i>Nature Genetics</i> , 2016, 48, 1535-1543.	21.4	326
174	Implementation of a Consensus Set of Hypervariable Mycobacterial Interspersed Repetitive-Unit Variable-Number Tandem-Repeat Loci in <i>Mycobacterium tuberculosis</i> Molecular Epidemiology. <i>Journal of Clinical Microbiology</i> , 2016, 54, 478-482.	3.9	6
175	First independent evaluation of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 47, 1587-1590.	6.7	87
176	Tuberculosis in migrants from 106 countries to Italy, 2008–2014. <i>European Respiratory Journal</i> , 2016, 47, 1273-1276.	6.7	12
177	Clinical implications of molecular drug resistance testing for <i>Mycobacterium tuberculosis</i> : a TBNET/RESIST-TB consensus statement. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 24-42.	1.2	123
178	Recommendations for the diagnosis of pediatric tuberculosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1-18.	2.9	29
179	<i>Mycobacterium absense</i> sp. nov., a scotochromogenic slow grower isolated from clinical respiratory specimens. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2016, 66, 450-456.	1.7	17
180	Emended description of <i>Mycobacterium abscessus</i> , <i>Mycobacterium abscessus</i> subsp. <i>abscessus</i> and <i>Mycobacterium abscessus</i> subsp. <i>bolletii</i> and designation of <i>Mycobacterium abscessus</i> subsp. <i>massiliense</i> comb. nov.. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2016, 66, 4471-4479.	1.7	190

#	ARTICLE	IF	CITATIONS
181	Pseudo-outbreak of <i>Mycobacterium gordonae</i> in a teaching hospital: importance of strictly following decontamination procedures and emerging issues concerning sterilization. <i>New Microbiologica</i> , 2016, 39, 25-34.	0.1	13
182	<i>Mycobacterium sherrisii</i> Pulmonary Disease, Burkina Faso. <i>Emerging Infectious Diseases</i> , 2015, 21, 2093-2094.	4.3	3
183	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. <i>European Respiratory Journal</i> , 2015, 46, 1841-1843.	6.7	0
184	Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease. <i>Tuberculosis</i> , 2015, 95, 179-185.	1.9	20
185	Epidemic MRSA clone ST22-IV is more resistant to multiple host- and environment-related stresses compared with ST228-I. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 757-765.	3.0	17
186	New Role for Human α -Defensin 5 in the Fight against Hypervirulent <i>Clostridium difficile</i> Strains. <i>Infection and Immunity</i> , 2015, 83, 986-995.	2.2	29
187	Evolutionary history and global spread of the <i>Mycobacterium tuberculosis</i> Beijing lineage. <i>Nature Genetics</i> , 2015, 47, 242-249.	21.4	466
188	Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal. <i>European Respiratory Journal</i> , 2015, 45, 292-294.	6.7	16
189	Diagnostic Performance of the New Version (v2.0) of GenoType MTBDR <i>sl</i> Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2961-2969.	3.9	111
190	Target Product Profile of a Molecular Drug-Susceptibility Test for Use in Microscopy Centers. <i>Journal of Infectious Diseases</i> , 2015, 211, S39-S49.	4.0	36
191	Defining the Needs for Next Generation Assays for Tuberculosis. <i>Journal of Infectious Diseases</i> , 2015, 211, S29-S38.	4.0	133
192	Universal health coverage and social support in Senegal: a comprehensive approach against tuberculosis. <i>European Respiratory Journal</i> , 2015, 46, 869-871.	6.7	6
193	Drug Resistance in <i>Mycobacterium tuberculosis</i> . <i>Chest</i> , 2015, 147, 1135-1143.	0.8	42
194	Integration of Published Information Into a Resistance-Associated Mutation Database for <i>Mycobacterium tuberculosis</i> . <i>Journal of Infectious Diseases</i> , 2015, 211, S50-S57.	4.0	32
195	PhyResSE: a Web Tool Delineating <i>Mycobacterium tuberculosis</i> Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1908-1914.	3.9	257
196	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	6.7	608
197	Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, S141-S146.	5.8	78
198	<i>Clostridium difficile</i> PCR Ribotype 018, a Successful Epidemic Genotype. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2575-2580.	3.9	44

#	ARTICLE	IF	CITATIONS
199	Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3876-3880.	3.9	41
200	Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in children: A prospective, multi-centre evaluation. <i>Journal of Infection</i> , 2015, 70, 392-399.	3.3	20
201	Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 686-696.	3.0	87
202	<i>Mycobacterium angelicum</i> sp. nov., a non-chromogenic, slow-growing species isolated from fish and related to <i>Mycobacterium szulgai</i> . <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2015, 65, 4724-4729.	1.7	9
203	Adaptation of <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Airways Influences Virulence of <i>Staphylococcus aureus</i> In Vitro and Murine Models of Co-Infection. <i>PLoS ONE</i> , 2014, 9, e89614.	2.5	138
204	<i>Mycobacterium tuberculosis</i> Pyrazinamide Resistance Determinants: a Multicenter Study. <i>MBio</i> , 2014, 5, e01819-14.	4.1	125
205	Molecular Diagnosis of Rifampin-Monoresistant Tuberculosis in Indian Patients: Problems with a Discordance Analysis. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3503-3503.	3.9	1
206	Molecular Epidemiology and Genotyping of <i>Mycobacterium tuberculosis</i> Isolated in Baghdad. <i>BioMed Research International</i> , 2014, 2014, 1-15.	1.9	12
207	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2014, 44, 23-63.	6.7	256
208	Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 633-647.	4.4	100
209	Unusual <i>Mycobacterial</i> Interspersed Repetitive-Unit Alleles in Loci 580 and 4348 among <i>Mycobacterium tuberculosis</i> Isolates in Albania. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4437-4438.	3.9	1
210	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1168-1176.	5.6	196
211	Tuberculosis elimination: theory and practice in Europe. <i>European Respiratory Journal</i> , 2014, 43, 1410-1420.	6.7	148
212	Survey of tuberculosis drug resistance among Tibetan refugees in India. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 655-662.	1.2	17
213	The roles of microRNAs on tuberculosis infection: Meaning or myth?. <i>Tuberculosis</i> , 2013, 93, 596-605.	1.9	52
214	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. <i>European Respiratory Journal</i> , 2013, 42, 252-271.	6.7	211
215	Alteration of human macrophages microRNA expression profile upon infection with <i>Mycobacterium tuberculosis</i> . <i>International Journal of Mycobacteriology</i> , 2013, 2, 128-134.	0.6	65
216	<i>Mycobacterium tuberculosis</i> Beijing Genotype Is Associated with HIV Infection in Mozambique. <i>PLoS ONE</i> , 2013, 8, e71999.	2.5	21

#	ARTICLE	IF	CITATIONS
217	First Evaluation after Implementation of a Quality Control System for the Second Line Drug Susceptibility Testing of Mycobacterium tuberculosis Joint Efforts in Low and High Incidence Countries. PLoS ONE, 2013, 8, e76765.	2.5	13
218	miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e80149.	2.5	70
219	Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiologica, 2013, 36, 111-20.	0.1	35
220	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1â€“. European Respiratory Journal, 2012, 40, 497-500.	6.7	20
221	Early tuberculosis treatment monitoring by XpertÂ® MTB/RIF: Figure 1â€“. European Respiratory Journal, 2012, 39, 1269-1271.	6.7	61
222	Availability of anti-tuberculosis drugs in Europe: Table 1â€“. European Respiratory Journal, 2012, 40, 500-503.	6.7	9
223	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1â€“. European Respiratory Journal, 2012, 39, 1263-1266.	6.7	10
224	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. Clinical Infectious Diseases, 2012, 54, 1379-1380.	5.8	67
225	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. European Respiratory Journal, 2012, 39, 619-625.	6.7	74
226	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	6.7	188
227	Is Real-Time PCR Better than Conventional PCR for Mycobacterium tuberculosis Complex Detection in Clinical Samples?. Journal of Clinical Microbiology, 2012, 50, 2810-2813.	3.9	29
228	GenoType MTBDR <i>sl</i> performance on clinical samples with diverse genetic background. European Respiratory Journal, 2012, 40, 690-698.	6.7	37
229	Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. European Respiratory Journal, 2012, 40, 442-447.	6.7	271
230	Factors Contributing to Epidemic MRSA Clones Replacement in a Hospital Setting. PLoS ONE, 2012, 7, e43153.	2.5	36
231	A Genome-Wide Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and Conservation Analysis. PLoS ONE, 2012, 7, e32723.	2.5	43
232	Genome-Wide Discovery of Small RNAs in Mycobacterium tuberculosis. PLoS ONE, 2012, 7, e51950.	2.5	70
233	Tbnet â€” Collaborative research on tuberculosis in Europe. European Journal of Microbiology and Immunology, 2012, 2, 264-274.	2.8	15
234	Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB. , 2012, , 1-13.		4

#	ARTICLE	IF	CITATIONS
235	High Prevalence of Shared International Type 53 among Mycobacterium tuberculosis Complex Strains in Retreated Patients from CÔte d'Ivoire. PLoS ONE, 2012, 7, e45363.	2.5	20
236	Interferon-Î release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal, 2011, 37, 88-99.	6.7	490
237	Xpert MTB/RIF test for tuberculosis. Lancet, The, 2011, 378, 481-482.	13.7	4
238	Tuberculosis in Kindergarten and Primary School, Italy, 2008-2009. Emerging Infectious Diseases, 2011, 17, 514-516.	4.3	19
239	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. European Respiratory Journal, 2011, 37, 1283-1285.	6.7	14
240	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. European Respiratory Journal, 2011, 38, 1221-1223.	6.7	52
241	Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey. European Respiratory Journal, 2011, 38, 222-224.	6.7	25
242	Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique. BMC Microbiology, 2010, 10, 195.	3.3	42
243	First Report of Hypervirulent Strains Polymerase Chain Reaction Ribotypes O27 and O78 Causing Severe Clostridium difficile Infection in Italy. Clinical Infectious Diseases, 2010, 50, 126-127.	5.8	20
244	Fatal vancomycin- and linezolid-resistant Enterococcus faecium sepsis in a child undergoing allogeneic haematopoietic stem cell transplantation for beta-thalassaemia major. Journal of Medical Microbiology, 2010, 59, 839-842.	1.8	12
245	Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14703-14708.	7.1	225
246	Extensively Drug-Resistant Tuberculosis, Burkina Faso. Emerging Infectious Diseases, 2010, 16, 840-842.	4.3	14
247	Tuberculosis in Europe: a problem of drug resistance or much more?. Expert Review of Respiratory Medicine, 2010, 4, 189-200.	2.5	19
248	LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. European Respiratory Journal, 2009, 33, 956-973.	6.7	487
249	Consensus Not Yet Reached on Key Drugs for Extensively Drug-Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	5.8	6
250	Severe community-onset infections in healthy individuals caused by community-acquired MRSA in an Italian teaching hospital, 2006-2008. Journal of Hospital Infection, 2009, 72, 271-273.	2.9	17
251	Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infectious Diseases, 2009, 9, 142.	2.9	21
252	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	6.7	163

#	ARTICLE	IF	CITATIONS
253	An outbreak caused by multidrug-resistant OXA-58-positive <i>Acinetobacter baumannii</i> in an intensive care unit in Italy. <i>Journal of Hospital Infection</i> , 2008, 68, 97-99.	2.9	12
254	Meticillin-resistant <i>Staphylococcus aureus</i> SCCmec type IV: nosocomial transmission and colonisation of healthcare workers in a neonatal intensive care unit. <i>Journal of Hospital Infection</i> , 2008, 69, 304-306.	2.9	5
255	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2008, 31, 1155-1159.	6.7	131
256	Genotype MTBDR plus : a Further Step toward Rapid Identification of Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , 2008, 46, 393-394.	3.9	73
257	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. <i>Clinical Infectious Diseases</i> , 2008, 46, 958-959.	5.8	35
258	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	6.7	67
259	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. <i>PLoS ONE</i> , 2008, 3, e3417.	2.5	88
260	Clinical and operational value of the extensively drug-resistant tuberculosis definition. <i>European Respiratory Journal</i> , 2007, 30, 623-626.	6.7	179
261	Use of a T-cell interferon- γ release assay for the diagnosis of tuberculous pleurisy. <i>European Respiratory Journal</i> , 2007, 30, 1173-1179.	6.7	150
262	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 857-871.	4.4	101
263	Extensively Drug-resistant Tuberculosis, Italy and Germany. <i>Emerging Infectious Diseases</i> , 2007, 13, 780-782.	4.3	96
264	Use of Commercial Interferon- γ Assays in Immunocompromised Patients for Tuberculosis Diagnosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 130-130.	5.6	18
265	Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN- γ Assay for the Diagnosis of <i>Mycobacterium tuberculosis</i> Infection. <i>Clinical Medicine and Research</i> , 2006, 4, 266-272.	0.8	14
266	Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in <i>Mycobacterium tuberculosis</i> Clinical Strains Isolated in Italy. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2485-2491.	3.9	98
267	Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. <i>European Respiratory Journal</i> , 2006, 28, 31-34.	6.7	107
268	Evaluation of chromogenic medium (ORSAB) for routine identification of methicillin resistant <i>Staphylococcus aureus</i> (MRSA). <i>New Microbiologica</i> , 2005, 28, 83-7.	0.1	0
269	<i>Mycobacterium tuberculosis</i> Complex Drug Resistance in Italy. <i>Emerging Infectious Diseases</i> , 2004, 10, 752-753.	4.3	7
270	mig-14 Is a Horizontally Acquired, Host-Induced Gene Required for <i>Salmonella enterica</i> Lethal Infection in the Murine Model of Typhoid Fever. <i>Infection and Immunity</i> , 2000, 68, 7126-7131.	2.2	31

#	ARTICLE	IF	CITATIONS
271	Macrophage-dependent induction of the Salmonella pathogenicity island 2 type III secretion system and its role in intracellular survival. <i>Molecular Microbiology</i> , 1998, 30, 175-188.	2.5	563
272	Epidemiological characteristics of <i>Pseudomonas aeruginosa</i> strains causing infection in an Italian general hospital. <i>European Journal of Epidemiology</i> , 1995, 11, 339-344.	5.7	3
273	Identification of the Bombesin Receptor on Murine and Human Cells by Cross-Linking Experiments. <i>Annals of the New York Academy of Sciences</i> , 1988, 547, 474-476.	3.8	0
274	Deregulation of the tyrosine kinase associated with the bombesin receptor in small cell lung carcinomas. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1752.	0.7	0
275	Proteins phosphorylated on tyrosine as markers of human malignancies. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1744-1745.	0.7	0
276	Laboratory diagnosis of tuberculosis. , 0, , 99-115.		1